Status and phase
Conditions
Treatments
About
This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age. The aim of the study is to evaluate MF59-adjuvanted influenza vaccine compared with non-adjuvanted influenza vaccine in the prevention of reverse transcription-polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B in subjects ≥65 years of age.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
In order to participate in this study, all subjects must meet ALL of the inclusion criteria described.
Exclusion criteria
In order to participate in this study, all subjects must not meet any of the exclusion criteria described below:
Bedridden subjects (i.e. confined to bed by sickness or old age).
Subjects that are incapacitated and because of that in need of a Legally Authorized Representative.
Receipt of any influenza vaccine within 6 months prior to enrollment or any plan to receive influenza vaccine while participating in the study.
Hypersensitivity, including allergy, to any component of vaccines whose use is foreseen in this study, or severe allergic reaction (e.g. anaphylaxis) to previous influenza vaccination.
Known history of Guillain-Barré syndrome or another demyelinating disease such as encephalomyelitis and transverse myelitis.
Clinical conditions representing a contra-indication to intramuscular administration of vaccines or blood draw.
Abnormal function of the immune system resulting from:
Receipt of immunoglobulins or any blood products within 180 days prior to informed consent.
Receipt of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the study vaccination, or planned use during the entire study period.
Acute (severe) febrile illness.
Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.
Study personnel or immediate family members (brother, sister, child, parent) or the spouse of study personnel.
Primary purpose
Allocation
Interventional model
Masking
35,800 participants in 2 patient groups
Loading...
Central trial contact
Use Central Contact; Clinical Trial Disclosure Manager
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal